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Introduction
Epidemiological and experimental evidence implicates
oestrogens in the aetiology of breast cancer. Most estab-
lished risk factors for breast cancer in humans are thought
to influence risk through hormone-related pathways [1],
increased concentrations of endogenous oestrogens are
strongly associated with increased risk for breast cancer
in postmenopausal women [2], and trials have shown that
the anti-oestrogens tamoxifen and raloxifene reduce the
incidence of breast cancer [3]. Furthermore, experimental
studies in animals have shown that oestrogens can
promote mammary tumours, and a decrease in exposure
to oestrogens, by performing an oophorectomy or giving
an anti-oestrogenic drug, has the reverse effect [4].
However, the effects of oestrogen alone do not fully
account for the relationships observed between breast
cancer and hormone-related risk factors. Other hormones,
such as progesterone [1], prolactin [5] and testosterone
[6], may also be important.
This article explores the evidence for the hypothesis that
exposure to oestrogen is a major determinant of risk for
breast cancer. It is not intended to be a comprehensive
review but rather focuses on recent epidemiological and
experimental data relating to the role of oestrogen in the
aetiology of breast cancer and possible mechanisms that
might account for the association. There are several forms
of oestrogen, the principal form in humans being oestra-
diol, but for convenience in this article we refer generally
to oestrogens except where it is necessary to be more
specific.
Reproductive risk factors, oestrogen and
breast cancer
Oestrogens have an essential role, together with other
hormones, in the development of the female sex organs
and secondary sex characteristics, the regulation of the
menstrual cycle and reproduction. Thus, it has been pro-
posed that the effects of many established reproductive
risk factors for breast cancer are mediated by hormonal
mechanisms, for the most part involving oestrogens [1].
Although risk for breast cancer increases with age, there
is a marked decline in the rate of increase in risk with age
following the loss of ovarian function, either as a result of a
bilateral oophorectomy or due to the menopause [7,8],
showing that hormone production by the ovaries is a
crucial risk factor for breast cancer in humans. The
duration of exposure to ovarian hormones seems to be
closely related to breast cancer risk: a 1-year delay in the
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Abstract
Epidemiological and experimental evidence implicates oestrogens in the aetiology of breast cancer.
Most established risk factors for breast cancer in humans probably act through hormone-related
pathways, and increased concentrations of circulating oestrogens have been found to be strongly
associated with increased risk for breast cancer in postmenopausal women. This article explores the
evidence for the hypothesis that oestrogen exposure is a major determinant of risk for breast cancer.
We review recent data on oestrogens and breast cancer risk, consider oestrogen-related risk factors
and examine possible mechanisms that might account for the effects of oestrogen. Finally, we discuss
how these advances might influence strategies for reducing the incidence of breast cancer.
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onset of menarche is associated with a 5% reduction in
risk for developing breast cancer in later life [9], and each
1-year delay in the onset of menopause is associated with
a 3% increase in risk [7].
Epidemiological studies have also firmly established asso-
ciations between risk for breast cancer and other repro-
ductive factors, including nulliparity (having no children) or
low parity, late age at first birth, and breast feeding [10].
After a transient increase in risk for breast cancer, peaking
at about 5 years after giving birth [11], having at least one
child is associated with a decrease in the long-term risk of
developing breast cancer compared with risk among the
nulliparous, and this protective effect increases with
number of children [12]. Each birth reduces the relative
risk of breast cancer by an average of 7% [12]. The reduc-
tion in risk per birth is greater for births at young ages than
older ages, such that women who have their first birth
before the age of 20 years have a 30% lower risk than
women with a first birth after the age of 35 years [13].
A mechanism involving oestrogens, and probably other
hormones, has been proposed to explain both the tran-
sient increase in risk and the reduced risk in the long term
associated with pregnancy. The very high serum levels of
oestrogens and progesterone during pregnancy stimulate
growth of the mammary epithelium and also promote the
differentiation of epithelial tissue, reducing the number of
epithelial structures most vulnerable to malignant transfor-
mation [14]. Thus, the short-term effect of pregnancy may
be to promote the growth of cancer if a malignant transfor-
mation is present in the breast, but in the longer term the
risk for breast cancer is reduced. In contrast, malignant
transformations are more likely to have accumulated in the
breast tissue of older women, and there might therefore
be a higher risk of cancer developing in these women
when breast cells are stimulated to divide during preg-
nancy. The effect of age at first birth highlights the impor-
tance of timing of exposure as a critical determinant of the
effects of steroid hormones such as oestrogen.
Breast feeding is associated with a modest decrease in
risk for breast cancer, above and beyond that associated
with multiple pregnancies (4% for every 12 months of
breast feeding) [12]. This effect might be due to the sup-
pression of ovulation, reducing exposure to ovarian hor-
mones.
Diet-related and lifestyle factors in relation to
breast cancer
Two diet-related factors, high alcohol intake [15] and
obesity [16], are established risk factors for breast cancer.
A moderate intake of alcohol (one unit a day) increases
risk by 7%, and higher intakes of alcohol increase risk in
an approximately linear fashion. The mechanism for this
effect remains unknown but has been proposed to involve
increased concentrations of circulating oestrogens
[15,17]. Breast cancer risk among postmenopausal
women is also strongly associated with body mass index
(BMI, an index of body weight independent of height, cal-
culated as body weight in kilograms divided by the square
of the height measured in metres). Risk for breast cancer
is increased by 30% among obese postmenopausal
women (with a BMI of more than 30kg/m2) compared with
those with a normal BMI (less than 25kg/m2) [16]. This
association is probably due to the relationship between
BMI and endogenous oestrogen concentrations because,
in postmenopausal women, circulating oestrogen concen-
trations are dependent on the extraglandular production of
oestrogen in the adipose tissue.
For premenopausal women, the lack of a positive associa-
tion of BMI with breast cancer risk [16] is consistent with
the facts that most oestrogen is produced by the ovaries
and that levels are homeostatically regulated by a negative
feedback system involving gonadotrophins (follicle-stimu-
lating hormone and luteinising hormone). Thus, oestrogen
concentrations in premenopausal women are not directly
affected by the levels of adipose tissue. Indeed, obesity in
premenopausal women has been linked to a slight
decrease in risk for breast cancer [16], possibly mediated
through an increase in the occurrence of anovulatory
cycles and a subsequent decrease in exposure to ovarian
progesterone among these women (see below). It has
been suggested that this decrease in breast cancer risk
due to obesity in early adulthood may continue into later
life, negating some of the increased risk of breast cancer
among women who remain obese after the menopause
[18]. Evidence for this comes from the finding that weight
gain from adolescence to adulthood is most strongly and
consistently associated with risk of postmenopausal
breast cancer [16], with weight gains of over 20kg asso-
ciated with an increase in risk of 40% [19].
Physical activity has also been observed to be associated
with a reduced risk for breast cancer in both pre-
menopausal and postmenopausal women. Most studies
have found a 20–40% decrease in risk of breast cancer
among the most physically active [16]. The effects of
physical activity on breast cancer risk may be mediated
through alterations in endogenous hormones including
oestrogens, energy balance, body mass and possibly
immune function [20]. In postmenopausal women this low
risk might be due in part to physical activity preventing
weight gain and obesity [20], although there is some evi-
dence to suggest that the effects of physical activity are
independent of weight control [21]. In premenopausal
women the effects of high levels of physical exercise may
be mediated by other mechanisms [20]. For example,
there is considerable evidence that intense physical activ-
ity can alter menstrual cycle characteristics, delay men-
arche and increase the probability of anovulatory cycles,241
amenorrhoea or oligomenorrhoea, thus reducing exposure
to ovarian hormones [20,22–24], and there is also some
promising evidence that even moderate exercise may be
beneficial [25–27].
Endogenous oestrogens and breast cancer in
humans
Direct evidence for a relationship between oestrogens and
risk of developing breast cancer comes from observational
studies that have found circulating and excreted oestro-
gen levels to be associated with risk for the disease [28].
Because breast cancer itself might affect hormone pro-
duction, it is necessary to conduct prospective studies of
oestrogens and breast cancer risk in which samples are
collected at the start of the study from healthy women,
who are then followed up with respect to cancer diag-
noses. Such investigations have considered pre-
menopausal and postmenopausal women separately
because the endogenous production of and exposure to
endogenous oestrogen varies greatly during a woman’s
lifespan. In premenopausal women, the predominant form
of circulating oestrogen is oestradiol secreted by the
ovaries in cyclical monthly patterns. After the menopause,
however, the production of oestrogens in the ovaries
ceases and the major source of oestradiol is by conver-
sion from oestrone, itself produced mostly through the
peripheral conversion of androgen precursors, predomi-
nantly androstenedione, in extraglandular tissue such as
adipose tissue [29].
A recent pooled analysis of nine prospective studies in
postmenopausal women, including 663 breast cancer
cases, found a highly significant increase in breast cancer
risk with increasing concentrations of oestradiol, free
oestradiol and oestrone in the blood [2]. Postmenopausal
women with relatively high serum oestrogen concentra-
tions had an approximately twofold risk of breast cancer
compared with postmenopausal women with relatively low
serum concentrations of sex hormones [2]. Studies have
also evaluated the relationship between urinary endoge-
nous oestrogens and breast cancer; recent results from
the largest prospective study of oestrogens and breast
cancer found women with a higher excretion of oestrone
and oestradiol to have a significantly increased risk for
breast cancer [30].
Data on oestrogen levels in premenopausal women and
breast cancer risk are sparse, with only five small prospec-
tive studies published so far [31–35]. Of the three larger
and more recent studies, two found a nonsignificant
increase in mean oestradiol concentrations among cases
in comparison with controls [33,34], and the third
reported significantly elevated levels of bioavailable
oestradiol and a nonsignificant increase in total oestradiol
in cases [35]. These results are compatible with the
oestrogen hypothesis, but the numbers studied are too
small, and the difficulties of appropriate adjustment for day
of menstrual cycle too complex, to allow any firm conclu-
sions.
A limitation with all these studies is that they rely on meas-
urements made from just one sample, and whereas meas-
urements in single samples from postmenopausal women
have been found to be fairly representative of long-term
circulating oestrogen concentrations, single sample mea-
surements from premenopausal women are less represen-
tative of average circulating concentrations [36,37]. The
reliable estimation of circulating oestrogen concentrations
in premenopausal women is complicated by the fluctuat-
ing levels of oestrogen over the course of the menstrual
cycle, such that the timing of the sample is a strong deter-
minant of the oestrogen concentration measured.
Binding proteins and the bioavailability of
oestrogens
The availability of oestrogen in tissues is determined not
only by the production of the hormone and concentrations
in circulation but also by the extent to which it is bound to
a binding protein, sex-hormone-binding globulin (SHBG).
Thus, high concentrations of SHBG decrease the propor-
tion of oestradiol that is able to leave the circulation and
enter the cells. SHBG might partly mediate the effects of
obesity in postmenopausal women because obesity is
associated with lower levels of SHBG [36] and an inverse
association has been observed between concentrations of
SHBG and breast cancer risk in postmenopausal women
[2]. So far, however, the few studies that have investigated
the relationship between SHBG and breast cancer risk in
premenopausal women have failed to find an association
[34,35,38].
Genetic determinants of endogenous
hormones in relation to breast cancer risk
The genetic control of oestrogen levels has recently
received much attention and with it the notion that sus-
ceptibility to breast cancer might in part be determined
through germline polymorphisms in metabolic genes,
specifically those encoding enzymes involved in the
biosynthesis and metabolism of oestrogens [39]. Further,
it has been suggested that small effects of individual poly-
morphisms in genes involved in steroid biosynthesis and
catabolism might be cumulative [40]. Such polymorphisms
might be particularly important among postmenopausal
women, in whom oestrogen production is not homeostati-
cally controlled by pituitary gonadotrophins. Several
recent epidemiological studies have observed an associa-
tion between risk for breast cancer and polymorphisms in
genes involved in oestrogen synthesis, such as CYP17
and  CYP19, and in HSD17B1, which codes for an
enzyme that converts oestrone to oestradiol [40,41].
However, other studies have not found an association
between such polymorphisms and breast cancer, and a
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biological relationship of these polymorphisms with circu-
lating oestrogens and oestrogen metabolites has yet to be
established (reviewed in [42,43]).
Variations in oestrogen catabolism may also influence risk
for breast cancer by causing differences in the cumulative
exposure to oestrogen, by influencing the balance
between different forms of oestrogen and by altering expo-
sure to the various metabolites, some of which might have
carcinogenic properties. In humans, oestrogens are
catabolised into hydroxy-oestrogens such as 16α-hydroxy-
lated oestrogens and 2-hydroxylated (catechol) oestro-
gens, which are then converted into methoxylated
metabolites. Polymorphisms in genes such as COMT,
which is involved in the methylation of oestrogens to harm-
less metabolites, have been the subject of epidemiological
studies [44]. Several studies have found women with the
low-activity  COMT allele to be at higher risk for breast
cancer [45–47]. However, other studies have failed to find
a significant association [48,49] or have found COMT to
be important only in certain histotypes or in conjunction
with other exposures [49,50].
Exogenous oestrogens and breast cancer
In the past 50 years, exposure to exogenous oestrogens
from a variety of sources has become increasingly
common, particularly from hormonal preparations for use
as contraceptives or to combat the symptoms of the
menopause. Hormonal contraception, using oestrogens
and progestins in various forms and doses, is now one of
the most widely used forms of contraception, being taken
by 200 million women worldwide in 1996 [51]. Similarly,
the prescription of hormone replacement therapy (HRT)
for older women, containing oestrogens with or without
progestins, has become common. In Britain, for example,
33% of women aged 50–64 are current users [52]. Given
the high prevalence of exposure to these exogenous
oestrogens, even small associated increases in risk for
breast cancer could have a substantial effect on the inci-
dence of breast cancer.
Oral contraceptives and breast cancer
In 1996, data from 54 published studies on use of the
combined contraceptive pill (containing an oestrogen and
a progestogen) in relationship to breast cancer risk were
brought together in a pooled analysis [53]. Women who
were currently using combined oral contraceptives or who
had used them in the past 10 years were found to be at
slightly higher risk of having breast cancer diagnosed (rel-
ative risk [95% confidence interval] in current user, 1.24
[1.15–1.33]; 1–4 years after stopping, 1.16 [1.08–1.23];
5–9 years after stopping, 1.07 [1.02–1.13]), although the
associated cancers tended to be localised to the breast
[53]. However, there was no evidence of a significant
excess risk of having breast cancer diagnosed 10 or more
years after ceasing to use the combined contraceptive pill
(relative risk 1.01 [0.96–1.05]) [53]. More recent results
are broadly compatible with these findings, but inconsis-
tencies remain and formulations are changing; further
research is therefore crucial [54–59].
HRT and breast cancer
So far there have been more than 60 analytical studies
investigating the relationship between menopausal HRT
and breast cancer risk. Data from these studies were
brought together in a pooled analysis [7], which found that
current users of HRT, or those who ceased use 1–4 years
previously, had a 2.3% excess risk of being diagnosed
with breast cancer for each year of use, an increase in risk
that is comparable with the effect of delaying menopause
for a year [7]. The excess risk of breast cancer among
women who had used HRT for 5 years or longer was
35%. This effect was reduced after ceasing use of HRT
and had largely, if not wholly, disappeared after about
5 years. These results did not vary significantly by type of
HRT, although the collaborative study had relatively little
power to assess relationships with combined oestro-
gen–progestin therapy. More recent studies have reported
that the long-term use of preparations containing prog-
estins is more detrimental than the use of oestrogen alone
[60,61]. Recent data from three randomised controlled
trials have confirmed that exposure to oestrogens plus
progestins for 5 years is associated with an approximate
26–30% increase in risk for breast cancer [62].
Phyto-oestrogens and breast cancer
The observation that breast cancer rates are lower in most
Asian countries than in Western Europe and the USA [63]
has given risen to hypotheses about the possible protec-
tive effects of foods rich in phyto-oestrogens, particularly
soybeans, which form an important part of the diet in
several Asian countries [64]. Phyto-oestrogens are natu-
rally occurring plant compounds (or their metabolites) that
are effectively weak exogenous oestrogens because they
can mimic or modulate the actions of more potent
endogenous oestrogens, usually by binding to oestrogen
receptors (ERs) [65]. It has also been suggested that they
might reduce risk by altering oestrogen metabolism away
from the production of genotoxic metabolites [66] or
through non-oestrogenic pathways [65].
Results from numerous animal studies suggest that high
intake of soy may confer a protective effect against breast
cancer [67], but the findings from studies in humans
remain equivocal [68]. Two early case-control analyses
suggested that high levels of dietary isoflavone intake may
be protective against breast cancer in premenopausal
women [69,70], but results from later analytical studies of
adult exposure and breast cancer risk have been inconsis-
tent [68]. Two recent case-control studies have sug-
gested that a high intake of isoflavone-rich foods during
adolescence may have a protective effect on risk for
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breast cancer in adulthood [71,72]. These findings
support the possibility that exposure to phyto-oestrogens
at critical periods of development might be an important
determinant of risk for breast cancer.
The proliferative effects of oestrogen
Oestrogens have a marked proliferative effect on breast
epithelial tissue in model systems [73]. Both endogenous
and exogenous oestrogens stimulate breast epithelial cell
mitosis, increasing the number of cell divisions and thus
the opportunity for random genetic errors [1,74]. Oestro-
gen concentrations may be important at all stages in the
development of breast neoplasms because the hormonal
stimulus to cell division continues all along the progres-
sion pathway [75]. The proliferative effects of oestrogens
are brought about on entering target cells, where they
bind with a receptor protein, which then binds to hormone
response elements on the nuclear DNA, activating or sup-
pressing specific sequences in the regulatory regions of
genes responsive to oestrogen that control cell growth
and differentiation [76].
The possible role of oestrogens as mutagens in the initia-
tion of breast tumorigenesis has also received much
scrutiny. Although early experimental data suggested that
oestradiol did not have any mutagenic properties because
no mutagenic activity was found in either bacterial or
mammalian cell test systems, more recent research has
suggested that oestrogens, and to a greater extent their
metabolites including catechol oestrogens and reactive
semiquinone/quinone intermediates, may act as weak pro-
carcinogens. They might induce direct and indirect free-
radical-mediated DNA damage, genetic instability, and
mutations in cells in culture and in vivo [77]. However,
even if oestrogens can induce genetic damage, the data
overall suggest that proliferative effects are likely to be the
most important mechanism by which this hormone acts to
influence the development of breast cancer.
It has also been suggested that oestrogens might have an
important influence on risk for developing breast cancer
through effects before the initiation of the disease [78].
Raised oestrogen levels during fetal life have been shown
to influence morphology of the mammary gland [79], and
increased levels are also thought to be responsible for the
persistence of epithelial structures (terminal end buds)
that are known to be sites of malignant transformation
[80]. Furthermore, results from animal models and indirect
human evidence indicate that exposure to elevated oestro-
gen levels in utero may increase the risk for developing
breast cancer in adulthood [79,81].
Epidemiological studies investigating the relationship
between breast cancer risk and oestrogen exposure in
utero have examined several perinatal factors, such as
high birth weight [82,83]. In six out of seven epidemiologi-
cal studies, birth weight has been found to be positively
associated with risk for breast cancer [82,84], although
several studies have also found low birth weight (less than
2500g) to be associated with a higher risk for breast
cancer [84]. This intriguing field relates to the suggestion
that certain perinatal factors are associated with high con-
centrations of maternal oestrogens in pregnancy [78] or
high levels of oestrogens in the infant postnatally [85].
However, these associations remain to be confirmed [86].
Sensitivity to oestrogen
The sensitivity of breast tissue to oestrogen is dependent
on the levels and types of ERs [76] and it is possible that
variation in breast cancer risk is, in part, attributable to
inter-individual variation in receptor levels in normal breast
tissue [87]. ER levels have been found to vary by age,
menopausal status and perhaps by ethnic group [88,89].
Sensitivity of breast tissue to oestrogens might also be
determined by the balance between the two ER types,
ER-α and ER-β. ER-β has a lower affinity for oestrogen
than ER-α and may decrease the sensitivity of ER-α to
oestrogen [90].
Other hormones and breast cancer risk
Whereas early hypotheses focused on oestrogens as
important hormonal determinants of breast cancer risk
[91], current epidemiological and experimental data indi-
cate that other hormones, such as progesterone [1], pro-
lactin [5] and testosterone [6], are also important in the
aetiology of breast cancer.
It has been proposed that progesterone augments the
effects of oestrogens on breast cancer development [1],
and this hypothesis has gained support from several lines
of evidence. Breast cell proliferation has been found to be
greatest during the luteal phase of the menstrual cycle [1],
when levels of progesterone are at their highest, and a
cross-sectional study of women undergoing breast biop-
sies found that the mitotic activity in the terminal ductal
lobular unit of the breast was greater in women taking
combined hormone preparations than in women using
oestrogen alone [92]. Furthermore, recent data indicate
that hormone replacement therapies containing both
oestrogens and progestogens have a greater detrimental
effect on risk for breast cancer than preparations contain-
ing oestrogens alone [61]. Progestins, like oestrogens, are
thought to exert their effects mainly through binding to
nuclear receptor proteins.
Epidemiological studies of prolactin have found that circu-
lating levels of the hormone are correlated with some
established risk factors for breast cancer; for example,
concentrations are higher in nulliparous than parous
women [93] and higher among women using certain types
of oral contraceptives than among those who were not
[94,95]. High concentrations of prolactin have also been
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found to be associated with increased risk for breast
cancer in prospective studies in postmenopausal women
[5]. In the largest prospective study so far, more than a
doubling in risk for breast cancer was observed among
women in the highest 25% of the prolactin distribution rel-
ative to those in the lowest 25%, independent of the
effects of concentrations of circulating oestrogens, andro-
gens and insulin-like growth factor-1 [96]. Prolactin, pro-
duced at the endocrine and autocrine/paracrine levels,
acts to stimulate the proliferation, survival and motility of
mammary epithelial cells through its interaction with
receptors at the cell surface [5].
Testosterone might also have a role in the aetiology of
breast cancer [6]. Results from a recent pooled analysis of
prospective studies in postmenopausal women estimated
that breast cancer risk among women in the top quintile of
exposure to endogenous testosterone was more than
double that of women in the lowest quintile [2]. However,
the mechanisms by which testosterone might influence
the risk for developing breast cancer remain unclear, as do
the effects of the androgen on the risk for premenopausal
breast cancer [6]. It may be that, in postmenopausal
women at least, testosterone is converted to oestrogen in
the breast.
Preventive strategies
The epidemiological evidence suggests that the risk of
breast cancer might be reduced by lowering lifetime expo-
sure to oestrogens through changes in lifestyle and repro-
ductive behaviour. At present the only clear
oestrogen-related risk factor for breast cancer that is
amenable to change is obesity after the menopause. Thus,
prudent advice is to maintain weight such that body mass
is below 25kg/m2. Other lifestyle changes that may have
protective effects mediated by oestrogens include min-
imising alcohol consumption and taking regular physical
exercise. Recent data suggest, too, that long-term use of
HRT should be avoided, unless there are strong clinical
indications. Voluntary changes in most of the important
reproductive risk factors such as parity and ages at men-
arche and menopause are not realistic, but extended
breast feeding will produce a small decrease in breast
cancer risk, in addition to its benefits for the child.
More radical measures including surgery, such as bilateral
prophylactic oophorectomy and/or mastectomy, or chemo-
prophylaxis may be considered for particularly susceptible
subgroups, such as those with a family history of breast
cancer or characteristics predisposing them to exposure
to high oestrogen levels. Bilateral oophorectomy has been
found to result in a 50–70% reduction in breast cancer
risk [97] although, in general, studies have focused only
on women with mutations in BRCA1/BRCA2. Trial data
show that the partial ER agonist tamoxifen and other ER
modulators such as raloxifene [98] reduce the incidence
of primary ER-positive breast cancer [3,99]. Aromatase
inhibitors [100], which suppress the peripheral conversion
of androstenedione to oestradiol through inhibition of the
aromatase enzyme, and agonists of gonadotrophin-releas-
ing hormone, which suppress ovarian function in pre-
menopausal women, have been shown to be effective in
the treatment of early breast cancer [101] and may be
developed for chemoprevention [1].
As these chemopreventatives may themselves be associ-
ated with detrimental effects, clinicians try to identify
women at particularly high risk for breast cancer, for whom
benefits of such interventions are likely to outweigh the
risks [102,103]. One method of identifying women at high
risk for the disease is to use mathematical models; one
such tool is the Gail model, which uses data on risk
factors to predict individualised risk for breast cancer
[104].
Conclusion
Oestrogens have a key role in the aetiology of breast
cancer, probably because of their proliferative effects.
Current data suggest that these steroid hormones
mediate the relationship between breast cancer and many
established risk factors, such as age at menarche, age at
menopause, and obesity in postmenopausal women.
However, the effects of other risk factors, such as parity
and breast feeding, may not be explained only by oestro-
gens; other hormones such as progesterone, prolactin
and testosterone may also be important. More work is
needed to clarify the effects of hormones on risk for breast
cancer and the mechanisms involved, as well as to unravel
the complex environmental and genetic determinants of
endogenous hormone concentrations.
Competing interests
None declared.
References
1. Pike MC, Spicer DV, Dahmoush L, Press MF: Estrogens,
progestogens, normal breast cell proliferation, and breast
cancer risk. Epidemiol Rev 1993, 15:17-35.
2. Endogenous Hormones and Breast Cancer Collaborative Group:
Endogenous sex hormones and breast cancer in post-
menopausal women: reanalysis of nine prospective studies. J
Natl Cancer Inst 2002, 94:606-616.
3. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S,
Boyle P: Overview of the main outcomes in breast-cancer pre-
vention trials. Lancet 2003, 361:296-300.
4. Dao TL: The role of ovarian steroid hormones in mammary
carcinogenesis. In:  Hormones and Breast Cancer. Edited by
Pike MC, Siiteri PK, Welsch CW. Cold Spring Harbor, New York:
Cold Spring Harbor Laboratory; 1981:281-295.
5. Clevenger CV, Furth PA, Hankinson SE, Schuler LA: The role of
prolactin in mammary carcinoma. Endocr Rev 2003, 24:1-27.
6. Lillie EO, Bernstein L, Ursin G: The role of androgens and poly-
morphisms in the androgen receptor in the epidemiology of
breast cancer. Breast Cancer Res 2003, 5:164-173.
7. Collaborative Group on Hormonal Factors in Breast Cancer:
Breast cancer and hormone replacement therapy: collabora-
tive reanalysis of data from 51 epidemiological studies of
52,705 women with breast cancer and 108,411 women
without breast cancer. Lancet 1997, 350:1047-1059.
Breast Cancer Research    Vol 5 No 5 Travis and Key245
8. Eerola H, Aittomaki K, Asko-Seljavaara S, Nevanlinna H, von
Smitten K: Hereditary breast cancer and handling of patients
at risk. Scand J Surg 2002, 91:280-287.
9. Hunter DJ, Spiegelman D, Adami HO, van den Brandt PA, Folsom
AR, Goldbohm RA, Graham S, Howe GR, Kushi LH, Marshall JR,
Miller AB, Speizer FE, Willett W, Wolk A, Yaun SS: Non-dietary
factors as risk factors for breast cancer, and as effect modi-
fiers of the association of fat intake and risk of breast cancer.
Cancer Causes Control 1997, 8:49-56.
10. Key TJ, Verkasalo PK, Banks E: Epidemiology of breast cancer.
Lancet Oncol 2001, 2:133-140.
11. Liu Q, Wuu J, Lambe M, Hsieh SF, Ekbom A, Hsieh CC: Tran-
sient increase in breast cancer risk after giving birth: postpar-
tum period with the highest risk (Sweden). Cancer Causes
Control 2002, 13:299-305.
12. Collaborative Group on Hormonal Factors in Breast Cancer:
Breast cancer and breastfeeding: collaborative reanalysis of
individual data from 47 epidemiological studies in 30 coun-
tries, including 50302 women with breast cancer and 96973
women without the disease. Lancet 2002, 360:187-195.
13. Ewertz M, Duffy SW, Adami HO, Kvale G, Lund E, Meirik O,
Mellemgaard A, Soini I, Tulinius H: Age at first birth, parity and
risk of breast cancer: a meta-analysis of 8 studies from the
Nordic countries. Int J Cancer 1990, 46:597-603.
14. Russo J, Wilgus G, Russo IH: Susceptibility of the mammary
gland to carcinogenesis: I. Differentiation of the mammary
gland as determinant of tumor incidence and type of lesion.
Am J Pathol 1979, 96:721-736.
15. Collaborative Group on Hormonal Factors in Breast Cancer:
Alcohol, tobacco and breast cancer: collaborative reanalysis
of individual data from 53 epidemiological studies, including
58,515 women with breast cancer and 95,067 women without
the disease. Br J Cancer 2002, 87:1234-1245.
16. International Agency for Research on Cancer: Weight Control
and Physical Activity. Lyon, France: IARC Press; 2002.
17. Dorgan JF, Baer DJ, Albert PS, Judd JT, Brown ED, Corle DK,
Campbell WS, Hartman TJ, Tejpar AA, Clevidence BA, Giffen CA,
Chandler DW, Stanczyk FZ, Taylor PR: Serum hormones and
the alcohol–breast cancer association in postmenopausal
women. J Natl Cancer Inst 2001, 93:710-715.
18. Hankinson S, Hunter D: Breast cancer. In: Textbook of Cancer
Epidemiology. Edited by Adami HO, Hunter D, Trichopoulos D.
Oxford: Oxford University Press; 2002:301-339.
19. Huang Z, Hankinson SE, Colditz GA, Stampfer MJ, Hunter DJ,
Manson JE, Hennekens CH, Rosner B, Speizer FE, Willett WC:
Dual effects of weight and weight gain on breast cancer risk.
JAMA 1997, 278:1407-1411.
20. Hoffman-Goetz L, Apter D, Demark-Wahnefried W, Goran MI,
McTiernan A, Reichman ME: Possible mechanisms mediating
an association between physical activity and breast cancer.
Cancer 1998, 83 (Suppl 3):621-628.
21. Thune I, Brenn T, Lund E, Gaard M: Physical activity and the risk
of breast cancer. N Engl J Med 1997, 336:1269-1275.
22. Feicht CB, Johnson TS, Martin BJ, Sparkes KE, Wagner WW Jr:
Secondary amenorrhoea in athletes. Lancet 1978,  2:1145-
1146.
23. Shangold MM, Levine HS: The effect of marathon training upon
menstrual function. Am J Obstet Gynecol 1982, 143:862-869.
24. Moisan J, Meyer F, Gingras S: Leisure physical activity and age
at menarche. Med Sci Sports Exerc 1991, 23:1170-1175.
25. Bernstein L, Ross RK, Lobo RA, Hanisch R, Krailo MD, Hender-
son BE: The effects of moderate physical activity on men-
strual cycle patterns in adolescence: implications for breast
cancer prevention. Br J Cancer 1987, 55:681-685.
26. Harlow SD, Matanoski GM: The association between weight,
physical activity, and stress and variation in the length of the
menstrual cycle. Am J Epidemiol 1991, 133:38-49.
27. Cooper GS, Sandler DP, Whelan EA, Smith KR: Association of
physical and behavioral characteristics with menstrual cycle
patterns in women age 29–31 years. Epidemiology 1996, 7:
624-628.
28. Key TJ: Serum oestradiol and breast cancer risk. Endocr Relat
Cancer 1999, 6:175-180.
29. Stanczyk FZ: Steroid hormones. In: Mishell’s Textbook of Infertil-
ity, Contraception, and Reproductive Endocrinology. 4th edition.
Edited by Lobo RA, Mishell DR, Paulson RJ, Shoupe D. Oxford:
Blackwell Science; 1997:47-66.
30. Onland-Moret NC, Kaaks R, van Noord PAH, Rinaldi S, Key T,
Grobbee DE, Peeters PHM: Urinary endogenous sex hormone
levels and the risk of postmenopausal breast cancer. Br J
Cancer 2003, 88:1394-1399.
31. Wysowski DK, Comstock GW, Helsing KJ, Lau HL: Sex
hormone levels in serum in relation to the development of
breast cancer. Am J Epidemiol 1987, 125:791-799.
32. Helzlsouer KJ, Alberg AJ, Bush TL, Longcope C, Gordon GB,
Comstock GW: A prospective study of endogenous hormones
and breast cancer. Cancer Detect Prev 1994, 18:79-85.
33. Rosenberg CR, Pasternack BS, Shore RE, Koenig KL, Toniolo
PG:  Premenopausal estradiol levels and the risk of breast
cancer: a new method of controlling for day of the menstrual
cycle. Am J Epidemiol 1994, 140:518-525.
34. Thomas HV, Key TJ, Allen DS, Moore JW, Dowsett M, Fentiman
IS, Wang DY: A prospective study of endogenous serum
hormone concentrations and breast cancer risk in pre-
menopausal women on the island of Guernsey. Br J Cancer
1997, 75:1075-1079.
35. Kabuto M, Akiba S, Stevens RG, Neriishi K, Land CE: A prospec-
tive study of estradiol and breast cancer in Japanese women.
Cancer Epidemiol Biomarkers Prev 2000, 9:575-579.
36. Thomas HV, Key TJ, Allen DS, Moore JW, Dowsett M, Fentiman
IS, Wang DY: A prospective study of endogenous serum
hormone concentrations and breast cancer risk in post-
menopausal women on the island of Guernsey. Br J Cancer
1997, 76:401-405.
37. Michaud DS, Manson JE, Spiegelman D, Barbieri RL, Sepkovic
DW, Bradlow HL, Hankinson SE: Reproducibility of plasma and
urinary sex hormone levels in premenopausal women over a
one-year period. Cancer Epidemiol Biomarkers Prev 1999, 8:
1059-1064.
38. Yu H, Shu XO, Shi R, Dai Q, Jin F, Gao YT, Li BD, Zheng W:
Plasma sex steroid hormones and breast cancer risk in
Chinese women. Int J Cancer 2003, 105:92-97.
39. Feigelson HS, Ross RK, Yu MC, Coetzee GA, Reichardt JK, Hen-
derson BE: Genetic susceptibility to cancer from exogenous
and endogenous exposures. J Cell Biochem Suppl 1996, 25:
15-22.
40. Feigelson HS, McKean-Cowdin R, Coetzee GA, Stram DO,
Kolonel LN, Henderson BE: Building a multigenic model of
breast cancer susceptibility: CYP17 and HSD17B1 are two
important candidates. Cancer Res 2001, 61:785-789.
41. Kristensen VN, Borresen-Dale AL: Molecular epidemiology of
breast cancer: genetic variation in steroid hormone metabo-
lism. Mutat Res 2000, 462:323-333.
42. Dunning AM, Healey CS, Pharoah PD, Teare MD, Ponder BA,
Easton DF: A systematic review of genetic polymorphisms and
breast cancer risk. Cancer Epidemiol Biomarkers Prev 1999, 8:
843-854.
43. Thompson PA, Ambrosone C: Molecular epidemiology of
genetic polymorphisms in estrogen metabolizing enzymes in
human breast cancer. J Natl Cancer Inst Monogr 2000:125-
134.
44. Comings DE, Gade-Andavolu R, Cone LA, Muhleman D, MacMur-
ray JP: A multigene test for the risk of sporadic breast carci-
noma. Cancer 2003, 97:2160-2170.
45. Yim DS, Parkb SK, Yoo KY, Yoon KS, Chung HH, Kang HL, Ahn
SH, Noh DY, Choe KJ, Jang IJ, Shin SG, Strickland PT, Hirvonen
A, Kang D: Relationship between the Val158Met polymor-
phism of catechol O-methyl transferase and breast cancer.
Pharmacogenetics 2001, 11:279-286.
46. Huang CS, Chern HD, Chang KJ, Cheng CW, Hsu SM, Shen CY:
Breast cancer risk associated with genotype polymorphism of
the estrogen-metabolizing genes CYP17, CYP1A1, and COMT:
a multigenic study on cancer susceptibility. Cancer Res 1999,
59:4870-4875.
47. Lavigne JA, Helzlsouer KJ, Huang HY, Strickland PT, Bell DA,
Selmin O, Watson MA, Hoffman S, Comstock GW, Yager JD: An
association between the allele coding for a low activity variant
of catechol-O-methyltransferase and the risk for breast
cancer. Cancer Res 1997, 57:5493-5497.
48. Kocabas NA, Sardas S, Cholerton S, Daly AK, Karakaya AE:
Cytochrome P450 CYP1B1 and catechol O-methyltrans-
ferase (COMT) genetic polymorphisms and breast cancer
susceptibility in a Turkish population. Arch Toxicol 2002,
76:643-649.
Available online http://breast-cancer-research.com/content/5/5/239246
49. Wedren S, Rudqvist TR, Granath F, Weiderpass E, Ingelman-
Sundberg M, Persson I, Magnusson C: Catechol-O-methyltrans-
ferase gene polymorphism and post-menopausal breast
cancer risk. Carcinogenesis 2003, 24:681-687.
50. Mitrunen K, Kataja V, Eskelinen M, Kosma VM, Kang D, Benhamou
S, Vainio H, Uusitupa M, Hirvonen A: Combined COMT and GST
genotypes and hormone replacement therapy associated
breast cancer risk. Pharmacogenetics 2002, 12:67-72.
51. Beral V, Hermon C, Reeves G, Key T: Breast cancer trends in
women in Sweden, the UK, and the USA in relation to their
past use of oral contraceptives. In: Hormonal Carcinogenesis II.
Proceedings of the Second International Symposium. Edited by
Li JJ, Li SA, Gustafsson J-A, Nandi S, Sekely LI. New York:
Springer-Verlag; 1996:99-106.
52. Million Women Study Collaborators: Patterns of use of hormone
replacement therapy in one million women in Britain,
1996–2000. BJOG 2002, 109:1319-1330.
53. Collaborative Group on Hormonal Factors in Breast Cancer:
Breast cancer and hormonal contraceptives: collaborative
reanalysis of individual data on 53 297 women with breast
cancer and 100 239 women without breast cancer from 54
epidemiological studies. Lancet 1996, 347:1713-1727.
54. Hankinson SE, Colditz GA, Manson JE, Willett WC, Hunter DJ,
Stampfer MJ, Speizer FE: A prospective study of oral contra-
ceptive use and risk of breast cancer (Nurses’ Health Study,
United States). Cancer Causes Control 1997, 8:65-72.
55. Magnusson CM, Persson IR, Baron JA, Ekbom A, Bergstrom R,
Adami HO: The role of reproductive factors and use of oral
contraceptives in the aetiology of breast cancer in women
aged 50 to 74 years. Int J Cancer 1999, 80:231-236.
56. Kumle M, Weiderpass E, Braaten T, Persson I, Adami HO, Lund
E: Use of oral contraceptives and breast cancer risk: The Nor-
wegian-Swedish Women’s Lifestyle and Health Cohort Study.
Cancer Epidemiol Biomarkers Prev 2002, 11:1375-1381.
57. Marchbanks PA, McDonald JA, Wilson HG, Folger SG, Mandel
MG, Daling JR, Bernstein L, Malone KE, Ursin G, Strom BL,
Norman SA, Wingo PA, Burkman RT, Berlin JA, Simon MS,
Spirtas R, Weiss LK: Oral contraceptives and the risk of breast
cancer. N Engl J Med 2002, 346:2025-2032.
58. Althuis MD, Brogan DR, Coates RJ, Daling JR, Gammon MD,
Malone KE, Schoenberg JB, Brinton LA: Hormonal content and
potency of oral contraceptives and breast cancer risk among
young women. Br J Cancer 2003, 88:50-57.
59. Dumeaux V, Alsaker E, Lund E: Breast cancer and specific types
of oral contraceptives: a large Norwegian cohort study. Int J
Cancer 2003, 105:844-850.
60. Ross RK, Paganini-Hill A, Wan PC, Pike MC: Effect of hormone
replacement therapy on breast cancer risk: estrogen versus
estrogen plus progestin. J Natl Cancer Inst 2000, 92:328-332.
61. Olsson HL, Ingvar C, Bladstrom A: Hormone replacement
therapy containing progestins and given continuously
increases breast carcinoma risk in Sweden. Cancer 2003, 97:
1387-1392.
62. Beral V, Banks E, Reeves G: Evidence from randomised trials
on the long-term effects of hormone replacement therapy.
Lancet 2002, 360:942-944.
63. International Agency for Research on Cancer: Globocan.  5th
edition. Lyon: IARC, 2001.
64. Setchell KD, Borriello SP, Hulme P, Kirk DN, Axelson M: Nons-
teroidal estrogens of dietary origin: possible roles in
hormone-dependent disease. Am J Clin Nutr 1984,  40:569-
578.
65. UK Food Standards Agency Committee on Toxicity: Working
Group on Phytoestrogens Draft Report, 2002. http://www.
foodstandards.gov.uk/multimedia/webpage/phytoreportworddocs
66. Xu X, Duncan AM, Wangen KE, Kurzer MS: Soy consumption
alters endogenous estrogen metabolism in postmenopausal
women. Cancer Epidemiol Biomarkers Prev 2000, 9:781-786.
67. Bingham SA, Atkinson C, Liggins J, Bluck L, Coward A: Phyto-
oestrogens: where are we now? Br J Nutr 1998, 79:393-406.
68. Peeters PHM, Keinan-Boker L, van der Schouw YT, Grobbee DE:
Phytoestrogens and breast cancer risk. Breast Cancer Res
Treat 2003, 77:171-183.
69. Lee HP, Gourley L, Duffy SW, Esteve J, Lee J, Day NE: Risk
factors for breast cancer by age and menopausal status: a
case-control study in Singapore. Cancer Causes Control 1992,
3:313-322.
70. Hirose K, Tajima K, Hamajima N, Inoue M, Takezaki T, Kuroishi T,
Yoshida M, Tokudome S: A large-scale, hospital-based case-
control study of risk factors of breast cancer according to
menopausal status. Jpn J Cancer Res 1995, 86:146-154.
71. Shu XO, Jin F, Dai Q, Wen W, Potter JD, Kushi LH, Ruan Z, Gao
YT, Zheng W: Soyfood intake during adolescence and subse-
quent risk of breast cancer among Chinese women. Cancer
Epidemiol Biomarkers Prev 2001, 10:483-488.
72. Wu AH, Wan P, Hankin J, Tseng CC, Yu MC, Pike MC: Adoles-
cent and adult soy intake and risk of breast cancer in Asian-
Americans. Carcinogenesis 2002, 23:1491-1496.
73. McManus MJ, Welsch CW: The effect of estrogen, proges-
terone, thyroxine, and human placental lactogen on DNA syn-
thesis of human breast ductal epithelium maintained in
athymic nude mice. Cancer 1984, 54:1920-1927.
74. Cohen SM, Ellwein LB: Cell proliferation in carcinogenesis.
Science 1990, 249:1007-1011.
75. Henderson BE, Feigelson HS: Hormonal carcinogenesis. Car-
cinogenesis 2000, 21:427-433.
76. Clemons M, Goss P: Estrogen and the risk of breast cancer. N
Engl J Med 2001, 344:276-285.
77. Jefcoate CR, Liehr JG, Santen RJ, Sutter TR, Yager JD, Yue W,
Santner SJ, Tekmal R, Demers L, Pauley R, Naftolin F, Mor G,
Berstein L: Tissue-specific synthesis and oxidative metabo-
lism of estrogens. J Natl Cancer Inst Monogr 2000:95-112.
78. Trichopoulos D: Hypothesis: does breast cancer originate in
utero? Lancet 1990, 335:939-940.
79. Hilakivi-Clarke L, Cho E, Raygada M, Kenney N: Alterations in
mammary gland development following neonatal exposure to
estradiol, transforming growth factor alpha, and estrogen
receptor antagonist ICI 182,780. J Cell Physiol 1997, 170:279-
289.
80. Russo IH, Russo J: Role of hormones in mammary cancer initi-
ation and progression. J Mammary Gland Biol Neoplasia 1998,
3:49-61.
81. McCormack VA, dos Santos Silva I, De Stavola BL, Mohsen R,
Leon DA, Lithell HO: Fetal growth and subsequent risk of
breast cancer: results from long term follow up of Swedish
cohort. BMJ 2003, 326:248-251.
82. Potischman N, Troisi R: In-utero and early life exposures in
relation to risk of breast cancer. Cancer Causes Control 1999,
10:561-573.
83. Kaijser M, Granath F, Jacobsen G, Cnattingius S, Ekbom A: Mater-
nal pregnancy estriol levels in relation to anamnestic and fetal
anthropometric data. Epidemiology 2000, 11:315-319.
84. Mellemkjaer L, Olsen ML, Sorensen HT, Thulstrup AM, Olsen J,
Olsen JH: Birth weight and risk of early-onset breast cancer
(Denmark). Cancer Causes Control 2003, 14:61-64.
85. Sedin G, Bergquist C, Lindgren PG: Ovarian hyperstimulation
syndrome in preterm infants. Pediatr Res 1985, 19:548-552.
86. Peck JD, Hulka BS, Savitz DA, Baird D, Poole C, Richardson BE:
Accuracy of fetal growth indicators as surrogate measures of
steroid hormone levels during pregnancy. Am J Epidemiol
2003, 157:258-266.
87. Khan SA, Rogers MA, Obando JA, Tamsen A: Estrogen receptor
expression of benign breast epithelium and its association
with breast cancer. Cancer Res 1994, 54:993-997.
88. Lawson JS, Field AS, Champion S, Tran D, Ishikura H, Trichopou-
los D: Low oestrogen receptor alpha expression in normal
breast tissue underlies low breast cancer incidence in Japan.
Lancet 1999, 354:1787-1788.
89. Shoker BS, Jarvis C, Sibson DR, Walker C, Sloane JP: Oestro-
gen receptor expression in the normal and pre-cancerous
breast. J Pathol 1999, 188:237-244.
90. Hall JM, McDonnell DP: The estrogen receptor beta-isoform
(ERbeta) of the human estrogen receptor modulates ERalpha
transcriptional activity and is a key regulator of the cellular
response to estrogens and antiestrogens. Endocrinology
1999, 140:5566-5578.
91. Korenman SG: Oestrogen window hypothesis of the aetiology
of breast cancer. Lancet 1980, 1:700-701.
92. Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA,
Haslam SZ: Hormone replacement therapy with estrogen or
estrogen plus medroxyprogesterone acetate is associated
with increased epithelial proliferation in the normal post-
menopausal breast. J Clin Endocrinol Metab 1999, 84:4559-
4565.
Breast Cancer Research    Vol 5 No 5 Travis and Key247
93. Kwa HG, Cleton F, Bulbrook RD, Wang DY, Hayward JL: Plasma
prolactin levels and breast cancer: relation to parity, weight
and height, and age at first birth. Int J Cancer 1981, 28:31-34.
94. Ismail MS, Serour GI, Torsten U, Weitzel H, Berlien HP: Elevated
serum prolactin level with high-dose estrogen contraceptive
pills. Eur J Contracept Reprod Health Care 1998, 3:45-50.
95. Wiegratz I, Kutschera E, Lee JH, Moore C, Mellinger U, Winkler
UH, Kuhl H: Effect of four different oral contraceptives on
various sex hormones and serum-binding globulins. Contra-
ception 2003, 67:25-32.
96. Hankinson SE, Willett WC, Michaud DS, Manson JE, Colditz GA,
Longcope C, Rosner B, Speizer FE: Plasma prolactin levels and
subsequent risk of breast cancer in postmenopausal women.
J Natl Cancer Inst 1999, 91:629-634.
97. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L,
Garber JE, Evans G, Isaacs C, Daly MB, Matloff E, Olopade OI,
Weber BL: Prophylactic oophorectomy in carriers of BRCA1 or
BRCA2 mutations. N Engl J Med 2002, 346:1616-1622.
98. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley
JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME,
Black D, Glusman JE, Costa A, Jordan VC: The effect of ralox-
ifene on risk of breast cancer in postmenopausal women:
results from the MORE randomized trial. Multiple Outcomes
of Raloxifene Evaluation. JAMA 1999, 281:2189-2197.
99. Gelber RD, Cole BF, Goldhirsch A, Rose C, Fisher B, Osborne
CK, Boccardo F, Gray R, Gordon NH, Bengtsson NO, Sevelda P:
Adjuvant chemotherapy plus tamoxifen compared with
tamoxifen alone for postmenopausal breast cancer: meta-
analysis of quality-adjusted survival. Lancet 1996, 347:1066-
1071.
100.Goss PE, Strasser K: Aromatase inhibitors in the treatment
and prevention of breast cancer. J Clin Oncol 2001, 19:881-
894.
101.Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J, Namer
M, Fogelman I, de Haes JC, de Matteis A, Stewart A, Eiermann W,
Szakolczai I, Palmer M, Schumacher M, Geberth M, Lisboa B:
Goserelin versus cyclophosphamide, methotrexate, and fluo-
rouracil as adjuvant therapy in premenopausal patients with
node-positive breast cancer: The Zoladex Early Breast Cancer
Research Association Study. J Clin Oncol 2002,  20:4628-
4635.
102.Clamp A, Danson S, Clemons M: Hormonal risk factors for
breast cancer: identification, chemoprevention, and other
intervention strategies. Lancet Oncol 2002, 3:611-619.
103.Domchek SM, Eisen A, Calzone K, Stopfer J, Blackwood A,
Weber BL: Application of breast cancer risk prediction models
in clinical practice. J Clin Oncol 2003, 21:593-601.
104.Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C,
Mulvihill JJ: Projecting individualized probabilities of develop-
ing breast cancer for white females who are being examined
annually. J Natl Cancer Inst 1989, 81:1879-1886.
Correspondence
Ruth Travis, Cancer Research UK, Epidemiology Unit, University of
Oxford, Oxford OX2 6HE, UK. Tel: 01865 302234; fax: 01865
310545; e-mail: ruth.travis@cancer.org.uk
Available online http://breast-cancer-research.com/content/5/5/239